The Definitive Guide to the Perimenopause and Menopause — Dr Louise Newson¶
This note is an AI-generated, full-text extraction intended to make the book's arguments legible without pretending to replace the source. It separates the author's claims, evidence, practical advice, and limitations; verify anything load-bearing against the book or a primary source.
Executive Summary¶
Dr Louise Newson, a UK-based GP and menopause specialist, argues that menopause is not a natural life stage to be endured but a long-term hormone deficiency requiring medical treatment. She contends that the medical establishment and society have failed women through misdiagnosis, stigma, and withholding effective treatment—primarily Hormone Replacement Therapy (HRT). The book combines personal anecdote, clinical case studies, practical advice, and advocacy for HRT as the "gold-standard treatment." It is strongest in its practical guidance for navigating healthcare appointments and normalizing taboo symptoms. However, it is significantly weaker in its overconfidence in HRT, reliance on anecdotal evidence, lack of citations for key claims, blurring of commercial interests with medical advice, and presentation of a contested medical framing as settled fact. The book is best understood as advocacy from a clinician-entrepreneur rather than neutral, evidence-based medical guidance.
The Central Thesis¶
Menopause is a long-term hormone deficiency—not merely a natural biological process—that can and should be medically managed with HRT. Newson argues that oestrogen receptors exist "in every cell throughout our bodies," so declining hormones affect nearly every system: mood, cognition, skin, joints, heart, immune function, and sleep. She contends that society and the medical establishment have stigmatized menopause, misdiagnosed symptoms as depression or dementia, and withheld effective treatment based on outdated fears about HRT risks. The book aims to empower women with knowledge to advocate for themselves and demand appropriate care.
Argument Map¶
Core premise: Menopause = hormone deficiency requiring treatment (contested framing)
Supporting claims: 1. Perimenopause is a distinct, often-missed stage that can begin a decade before periods stop 2. Symptoms are far broader than hot flushes—affecting mood, cognition, skin, joints, heart, and immune function 3. Taboo symptoms (vaginal dryness, urinary problems, low libido) are underdiscussed but treatable 4. HRT is the "gold-standard treatment" that corrects deficiency, with risks that are overstated and benefits that are underappreciated 5. Antidepressants are overprescribed for menopause-related mood changes, which are fundamentally different from clinical depression 6. Early menopause and cancer-treatment-induced menopause require prompt, aggressive treatment 7. Women must become informed self-advocates to navigate a poorly trained healthcare system
Evidence types used: Personal anecdote, clinical case studies, survey data (some from Newson's own organization), selective citation of studies, UK guideline references, expert quotes from allied professionals
Weaknesses: Heavy reliance on anecdote, lack of citations for many statistical claims, selective interpretation of risk evidence, commercial conflicts of interest, ideological framing presented as settled science
Core Concepts and Frameworks¶
Hormone deficiency model: Menopause reframed from natural process to medical condition requiring intervention. This is a contested position, not settled science.
Oestrogen receptor framework: Oestrogen receptors exist throughout the body, so hormone decline affects multiple systems. Used to explain wide symptom range.
Perimenopause as distinct stage: Transition period when hormones fluctuate unpredictably, symptoms can begin years before periods stop. Diagnosis should be based on symptoms and age, not blood tests.
Body-identical vs. synthetic vs. compounded bioidentical HRT: Newson strongly advocates for body-identical HRT (molecularly identical to human hormones), warns against compounded bioidentical HRT from private clinics, and criticizes older synthetic formulations.
Transdermal superiority: Patches, gels, and sprays are presented as safer than oral tablets because they bypass the liver, reducing blood clot risk.
Mood fluctuation vs. clinical depression: Menopause-related mood changes are cyclical and episodic, correlating with menstrual cycle phases, unlike the continuous low mood of clinical depression.
"Meno-stop": Anecdotal term for sudden, treatment-induced menopause (e.g., from cancer therapy), contrasted with gradual natural transition.
Detailed Chapter or Part Walk-through¶
Introduction and Author Positioning¶
Newson presents herself as a GP, menopause specialist, director of Newson Health Ltd, founder of the Menopause Charity, and creator of the Balance app. She claims to be "one of the UK's leading experts on the menopause." Her authority is asserted through professional roles, media appearances, and personal experience with perimenopause. Readers should note this is self-presentation in a commercial book—her expertise is asserted rather than independently verified within this text.
Chapter 1: Change before 'The Change': the Perimenopause¶
Newson distinguishes perimenopause (transition period of fluctuating hormones, symptoms can begin a decade before periods stop) from menopause (12 months after last period). She argues that diagnosis for women over 45 should be based on symptoms and period changes, not hormone blood tests, which she calls "unreliable."
Evidence: Personal anecdote (Newson failed to recognize her own perimenopause), case study of Claire (age 40-41, multiple misdiagnoses before HRT resolved symptoms), unattributed statistics (1 in 20 women experience menopause between 40-45, 1 in 100 before 40, more than one-third wait at least a year for treatment).
Practical advice: Don't wait for treatment if symptoms affect daily life; don't stop contraception prematurely (HRT is not contraception); Mirena coil serves dual purposes; talk to female relatives about menopause timing.
Weaknesses: No citations for statistical claims; single case study presented as representative; commercial interests blurred with medical advice; the claim that she "was unable to open an NHS menopause clinic as there was insufficient funding and interest" is presented without evidence.
Chapter 2: What to Expect: Common Symptoms¶
Newson argues that perimenopause and menopause produce a far wider range of symptoms than commonly recognized, affecting nearly every body system due to oestrogen receptors throughout the body.
Symptom categories: Period changes and hot flushes (75% of women experience, exact mechanism "not known"), mood and cognition (women describe "uncontrollable rage," some convinced they have dementia), physical symptoms (joint pain, weight gain, skin changes, bone loss, migraines).
COVID-19 connection: Newson argues oestrogen appears protective against severe COVID-19, citing a study of ~70,000 patients showing women on HRT had >50% lower mortality risk. She claims post-menopausal women have worse outcomes, and that long COVID and perimenopause share symptom profiles. She recommends all women attending long COVID clinics be asked about menopause and offered HRT.
Weaknesses: COVID-19 section is speculative—emerging evidence presented as settled; online survey of 1,294 women is self-selected, non-random; no discussion of confounding variables (women on HRT may have better healthcare access); many symptoms have multiple causes beyond hormones.
Chapter 3: Spotlight on Taboo Symptoms¶
Newson addresses vaginal dryness, urinary problems, and low sex drive as underdiscussed but treatable symptoms.
Vaginal dryness: Oestrogen decline thins tissues; affects daily activities, not just sex. Treatments include systemic HRT, local vaginal oestrogen (described as safe for long-term use with "no associated risks"), and non-hormonal moisturizers and lubricants.
Urinary problems: Oestrogen affects pelvic floor health. Treatments include pelvic-floor exercises (detailed instructions from physiotherapist Nicola Mulkeen), referral to pelvic-floor physiotherapist, and vaginal oestrogen or HRT.
Low sex drive: Declining oestrogen and testosterone directly affect libido; fatigue and vaginal dryness compound the issue. Newson claims many women haven't had intercourse for 1-2 years "not because they don't want to, but because they can't physically."
Weaknesses: Claims vaginal oestrogen has "no associated risks" without qualification—an absolute statement that may not hold for all patients (e.g., those with hormone-sensitive cancers); only one study cited (and dismissed as too low); "the majority of women I speak to haven't had intercourse for at least one or two years" is clinical observation, not population-level data.
Chapter 4: HRT and Other Treatment Options¶
Newson presents HRT as the "gold-standard treatment" and engages extensively with the breast cancer controversy.
Key claims: Transdermal oestrogen has no increased blood clot risk; micronized progesterone has no increased clot risk; women under 51 have no increased breast cancer risk from HRT; oestrogen-only users have 25% lower breast cancer risk; no study shows increased breast cancer mortality from HRT.
Dismissal of major studies: Newson critiques the 2002 Women's Health Initiative study (participants were older, average 63, often overweight, used older progestogens) and the 2019 Oxford study (observational, showing association not causation). She argues lifestyle factors (obesity, alcohol, inactivity) pose higher breast cancer risks than HRT.
Long-term health benefits: Newson claims 50% reduced risk of heart problems, stroke, and vascular dementia; greater cardiovascular benefit than blood-pressure or cholesterol medications for women under 60; reduced risk of osteoporosis, Alzheimer's, osteoarthritis, depression, Type 2 diabetes, and bowel cancer. These claims lack specific citations in the excerpt.
Practical guidance: Detailed instructions for applying gels, sprays, patches, and taking micronized progesterone. Newson states there is no fixed cut-off age for HRT and reports prescribing to a woman in her 90s.
Weaknesses: The author's dismissal of major studies represents selective interpretation; she does not present counter-evidence or acknowledge that some meta-analyses find small but statistically significant risks for combined HRT; the claim that she can visually identify HRT users is anecdotal and unsupported; the assertion that HRT can be taken "for ever" is controversial with long-term risks not discussed.
Chapter 5: Advice for Women Going through an Early Menopause¶
Newson argues that early menopause (40-45) and premature ovarian insufficiency (POI, before 40) are underdiagnosed and poorly managed.
Key points: Diagnosis requires FSH blood tests (repeated due to fluctuation), bone-density scan, and additional tests. HRT should continue until at least age 51 (natural menopause age). Younger women typically need higher hormone doses. 5-10% of women with POI may still conceive naturally.
Evidence: 2019 study finding women under 40 with premature menopause were nearly twice as likely to experience a non-fatal cardiovascular event before age 60. Case study of Hayley (diagnosed with POI at 14, minimal follow-up, struggled for over two decades).
Weaknesses: The Hayley case study is emotionally powerful but represents a single experience; Newson claims HRT "is by far the most appropriate treatment" without discussing potential risks or contraindications for younger women; no mention of potential risks of long-term HRT use in younger women.
Chapter 6: Menopause and Mental Health¶
Newson argues that hormone-related mood changes are fundamentally different from clinical depression and require different interventions—primarily HRT rather than antidepressants.
Distinguishing features: Clinical depression involves continuous low mood lasting weeks or months; menopause-related mood changes fluctuate, often correlating with menstrual cycle phases.
Evidence: Newson states the highest suicide rate among females is in the 50-54 age group—"precisely the average age of menopause"—and calls this "no coincidence" (no citation provided). A 2019 study of nearly 3,000 UK women by Newson's own organization found 66% had been offered or given antidepressants for menopause-related low mood. Case study of Kate (55) whose panic attacks, brain fog, and physical pains resolved after HRT.
Strong warning against antidepressants: Newson argues they don't address hormone deficiency, can cause side effects, and don't provide long-term protective benefits against heart disease and osteoporosis like HRT does.
Weaknesses: The suicide rate statistic is presented as evidence of a causal link without controlling for other factors; Newson cites research from her own organization and promotes her own app; the chapter frames HRT as the "correct" answer and antidepressants as a systemic failure without acknowledging that some women may genuinely need both or different treatments.
Chapter 7: Menopause and Sleep¶
Newson argues that hormonal changes are a primary, often overlooked, cause of sleep disruption during perimenopause and menopause.
Hormonal mechanisms: Oestrogen helps process serotonin (precursor to melatonin); progesterone increases GABA (calming neurotransmitter); low testosterone is associated with sleep problems. No citations provided for these specific claims.
Sleep quality vs. quantity: Newson endorses the National Sleep Foundation's four determinants: spending at least 85% of time in bed asleep, falling asleep within 30 minutes, waking no more than once per night, being awake for no more than 20 minutes after initially falling asleep.
Evidence: One controlled study cited—a 2019 sleep study dividing healthy adults into three groups (9 hours/night, 5 hours/night, and 5 hours/night with weekend "catch-up"). The catch-up group gained weight and had lower insulin sensitivity. Notably, the study was not conducted on menopausal women specifically. Case study of Wendy (48) whose sleep improved within days after HRT.
Practical advice: Consistent bedtime, "write your worries away" journaling, cotton bedding, split-tog duvets, fans, avoiding caffeine after mid-afternoon, limiting alcohol. Controversially, Newson advises against sleeping naked (claims sweat stays on skin, prolonging cooling—no citation offered).
Weaknesses: Heavy reliance on anecdotal evidence; the 2019 sleep study is the only controlled evidence cited and was not conducted on menopausal women; no discussion of non-hormonal sleep aids (melatonin, CBT-I, prescription sleep medications); the advice against sleeping naked contradicts common advice for night sweats.
Chapter 8: Exercise for a Better Menopause¶
Newson frames exercise as integral to managing menopause, particularly for bone health, cardiovascular disease, dementia, and weight maintenance.
Key exercise types: Weight-bearing exercise (brisk walking, dancing, aerobics) and strength exercise (yoga, Pilates, resistance bands, weights) for bone health.
The "New Rules": Newson advises women not to compete with their "younger self," framing perimenopause as a period of reduced capacity due to hormone deficiency. She advocates for integration over intensity—scheduling exercise like a work meeting, using lunch breaks, taking stairs, doing squats while waiting for the kettle to boil.
Evidence: No studies, patient cases, or data specific to menopausal women. The advice is generic and could apply to any adult. Newson cites UK guidelines for adults aged 19-64: 30 minutes of moderate-intensity exercise five times per week, plus strength exercise at least two days per week.
Weaknesses: No menopause-specific evidence cited; overly optimistic framing (after HRT, "your energy and appetite for activity should return"—assumes HRT resolves all symptoms); no strategies offered for exercising despite fatigue, joint pain, or hot flushes; the advice to "build strength exercises into your daily life" could contradict earlier instructions for proper form, increasing injury risk.
Chapter 9: Optimizing Your Nutrition during the Menopause¶
Newson argues that food should be viewed "as a form of medicine" and that nutrition complements medical treatments like HRT.
Key nutrients: Calcium (700mg daily UK guidelines), Vitamin D (10mcg/day supplements recommended September to March), Magnesium (270mg daily, many women find supplements helpful for sleep and headaches), low-GI foods, fibre (30g daily), Omega-3 (at least one portion of oily fish weekly), phytoestrogens (isoflavone supplements "not recommended for women with a history of breast cancer").
Gut health: Newson connects gut symptoms to hormonal fluctuations, recommending HRT consultation and prebiotic/probiotic foods.
Foods to limit: Ultra-processed foods and alcohol ("anything more than one small glass of wine per day" is considered excessive).
Weaknesses: Evidence base is thin—only two footnotes (for calcium and vitamin D guidelines); claims about magnesium's effects on sleep and headaches are based on anecdotal reports from her clinic, not cited studies; phytoestrogen section does not quantify their effectiveness; gut health section lacks citations.
Chapter 10: Going through the Menopause Due to Cancer Treatment¶
Newson argues that cancer treatment-induced menopause is fundamentally different from natural menopause—sudden rather than gradual—but that effective symptom management is available.
Causes: Surgery (oophorectomy), chemotherapy (damages eggs), radiotherapy to pelvic area, hormone treatments for breast cancer (Tamoxifen, aromatase inhibitors, ovarian ablation/suppression).
Key concepts: Menopause can be temporary or permanent depending on age and treatment type. Fertility conversations must happen before cancer treatment. Menopausal symptoms and cancer treatment side-effects are often indistinguishable.
The "Meno-Stop" concept: Through case study of Kelly (42, cervical cancer), Newson introduces the idea that treatment-induced menopause is a sudden, sharp hormonal cessation.
Treatment options: HRT recommended for non-hormone-dependent cancers; for hormone-dependent cancers, presented as an individualized decision with the author asserting benefits outweigh risks despite lack of "good-quality evidence" of harm. Vaginal oestrogen described as safe even for oestrogen receptor-positive cancers.
Weaknesses: Newson presents HRT as overwhelmingly beneficial even for hormone-dependent cancers while acknowledging the evidence is not "good-quality"—a significant weakness; she states vaginal oestrogen "can be safely used by the majority of women on a regular basis" and that women with oestrogen receptor-positive cancer "can still usually safely use vaginal oestrogens," which contradicts some oncological guidelines; the excerpt relies heavily on anecdotal case studies.
Chapter 11: Questions to Ask Your Healthcare Professional and Conclusion¶
Newson argues that the healthcare system systematically fails perimenopausal and menopausal women due to profound knowledge gaps among medical professionals.
The healthcare failure: Newson states her own menopause training was "non-existent," leading to misdiagnosis. She argues doctors remain reluctant to prescribe HRT based on "misreported findings" and "poor-quality research."
Evidence: 2020 Mumsnet/Gransnet survey of 1,500 UK women: one-third sought GP help, 26% visited three times or more before receiving appropriate treatment. Case study of Marie (51) who saw multiple doctors before receiving HRT.
Practical tools: Ten key questions to ask, six steps for successful appointments, resources (Balance app, British Menopause Society clinic list, symptom sheet from her website).
Four takeaways: Don't delay seeking help; you are the expert on your body; good care isn't just medicine (diet, exercise, mental health); talk openly about experiences.
Weaknesses: Newson calls HRT the "gold-standard treatment" without adequately acknowledging contraindications; no discussion of risks or contraindications for long-term HRT use; the claim that menopause "really can be an enjoyable time of your life" may feel dismissive to women with severe symptoms or those who cannot take HRT; Newson repeatedly directs readers to her own website, app, and private clinic; the resource list includes commercial entities alongside clinical guidelines; no counter-evidence presented about HRT risks.
Evidence, Examples, and Intellectual Basis¶
Types of evidence used: - Personal anecdote: Newson's own perimenopause experience, her yoga practice - Clinical case studies: Claire (misdiagnosed perimenopause), Kate (mood symptoms resolved with HRT), Wendy (sleep improved with HRT), Stephanie (symptoms resolved with HRT), Julia (restarted HRT at 60), Hayley (POI at 14), Kelly (cancer treatment-induced menopause), Marie (multiple doctor visits) - Survey data: 2019 study of nearly 3,000 UK women by Newson's own organization (66% offered antidepressants); 2020 Mumsnet/Gransnet survey of 1,500 UK women - Selective study citations: COVID-19 study of ~70,000 patients; 2019 sleep study (not on menopausal women); 2019 review of psychological interventions; study of 1,750 women on mindfulness; 2019 study on cardiovascular events in early menopause - UK guideline references: NICE guidelines, National Sleep Foundation, UK dietary guidelines - Expert quotes: Dermatologist Dr Sajjad Rajpar, hairdresser Matthew Curtis, physiotherapist Nicola Mulkeen, NHS insomnia specialist Kathryn Pinkham
Intellectual basis: The book is grounded in Newson's clinical experience as a menopause specialist and her interpretation of existing research. It is not a systematic review or meta-analysis. The evidence base is thin for a book claiming to be "definitive"—many key claims lack citations, and the author relies heavily on anecdotal case studies and her own clinical observations.
What is missing: No discussion of randomised controlled trials for HRT's efficacy on most symptoms; no systematic comparison of HRT versus alternatives; no discussion of women for whom HRT is contraindicated; no balanced presentation of risks; no discussion of non-hormonal treatment options in depth.
Practical Recommendations¶
For diagnosis: Women over 45 should be diagnosed based on symptoms and age, not blood tests. Keep a symptom diary (use the Balance app). Talk to female relatives about menopause timing.
For treatment: HRT is presented as the "gold-standard." Newson recommends transdermal oestrogen (patches, gels, sprays) over oral tablets. Micronized progesterone is preferred over synthetic progestogens. Testosterone can be added for persistent fatigue, brain fog, or low libido. There is no fixed cut-off age for HRT.
For contraception: Do not stop contraception prematurely. The Mirena coil serves dual purposes. Stop contraception 2 years after last period if under 50, 1 year if over 50, or safely at age 55.
For healthcare appointments: Request double appointments, prepare symptom lists, be honest, take notes, seek second opinions. Ask ten specific questions about diagnosis and treatment rationale.
For lifestyle: Exercise (30 minutes moderate-intensity five times per week plus strength exercise two days per week), nutrition (view food as medicine, limit ultra-processed foods and alcohol), sleep hygiene (consistent bedtime, journaling, cotton bedding), mindfulness and CBT for mood.
For cancer patients: Fertility conversations must happen before treatment. HRT is recommended for non-hormone-dependent cancers; individualized decision for hormone-dependent cancers. Vaginal oestrogen described as safe even for oestrogen receptor-positive cancers.
What Is Persuasive¶
Normalizing taboo symptoms: Newson's discussion of vaginal dryness, urinary problems, and low libido is valuable and destigmatizing. She provides practical, actionable advice that many women will find helpful.
Highlighting diagnostic failures: The case studies of women seeing multiple doctors before receiving appropriate care are compelling and likely reflect real systemic problems in menopause care.
Distinguishing mood changes from clinical depression: The observation that menopause-related mood changes are cyclical and episodic rather than continuous is clinically useful and may prevent misdiagnosis.
Practical appointment guidance: The ten questions and six steps for healthcare appointments are specific, actionable tools that could genuinely help women advocate for themselves.
Warning against compounded bioidentical HRT: Newson's clear distinction between regulated body-identical HRT and unregulated compounded bioidentical HRT is responsible and evidence-based.
Addressing early menopause and cancer treatment: The specific guidance for these populations is detailed and addresses genuine gaps in care.
Limitations, Contested Claims, and What Is Missing¶
Overconfidence in HRT: Newson presents HRT as a near-universal solution with minimal risks. She dismisses legitimate concerns about breast cancer risk from combined HRT without presenting counter-evidence. The claim that HRT can be taken "for ever" is controversial, and long-term risks are not discussed.
Selective evidence use: Newson critiques studies showing HRT risks (Women's Health Initiative, 2019 Oxford study) while embracing studies showing benefits—without acknowledging that some benefit claims also rely on observational data. She does not present a balanced assessment of the evidence.
Anecdotal dominance: The book relies heavily on clinical case studies and Newson's personal experience. While compelling, these are not generalizable evidence. No controlled studies, systematic reviews, or meta-analyses are cited for most claims.
Lack of citations: Many statistical claims (1 in 20 women experience menopause between 40-45, 10% of bone mass lost in first five years, highest suicide rate in 50-54 age group) are presented without citations. Readers cannot verify their source or methodology.
Commercial conflicts of interest: Newson repeatedly directs readers to her own website, Balance app, and private clinic. The line between evidence-based medicine and self-promotion is blurred. Her statement that she "was unable to open an NHS menopause clinic as there was insufficient funding and interest" is presented without evidence.
Ideological framing: The characterization of menopause as "hormone deficiency" rather than natural biological process is a contested medical framing, not settled science. Newson presents it as self-evident rather than as one perspective within ongoing medical debate.
Missing discussion of risks: The book provides limited discussion of HRT contraindications, side effects, or women for whom HRT is unsuitable. No discussion of non-hormonal treatment options in depth.
UK-centric: The book focuses almost entirely on the UK healthcare system. Readers elsewhere would need to adapt the advice significantly.
Contradictions within the text: Newson advises against sleeping naked (no citation) while also recommending cotton bedding and fans for night sweats. She dismisses blood tests as "unreliable" but promotes systematic symptom tracking without addressing its validation. She says the progestogen-only pill "is not a treatment for the perimenopause" but then notes it helped a patient's migraines and anxiety.
What is missing: No discussion of digestive symptoms, cognitive behavioural therapy for insomnia, melatonin supplements, prescription sleep medications, or alternative treatments for women who cannot take HRT. No discussion of when cognitive symptoms warrant serious investigation for dementia. No discussion of confounding variables in the COVID-19 study (women on HRT may have better healthcare access and be more health-conscious).
Bottom Line¶
The Definitive Guide to the Perimenopause and Menopause is a passionate, patient-empowerment book that effectively normalizes taboo symptoms, highlights genuine diagnostic failures in menopause care, and provides practical tools for navigating healthcare appointments. Its strengths lie in its accessible explanations, destigmatizing approach, and actionable guidance. However, the book is significantly weakened by its overconfidence in HRT, heavy reliance on anecdotal evidence, lack of citations for key claims, selective interpretation of risk evidence, and blurring of commercial interests with medical advice. The framing of menopause as "hormone deficiency" rather than natural biological process is a contested position presented as settled fact. Readers should approach the book as advocacy from a clinician-entrepreneur rather than neutral, evidence-based medical guidance, and should supplement with balanced information about HRT risks, contraindications, and alternative treatments. For women seeking to understand their options and advocate for better care, the book offers useful tools—but it should not be the only source consulted.